Soleno Therapeutics, Inc.
SLNO
Updated: 23/09/2026, 17:40:26
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
No summaries found.
- Share price
- $53.01
- Market cap
- $2.76B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Anish Bhatnagar
- Employees
- 115
- IPO date
- 13/11/2014
- Beta
- -2.217
- Last dividend
- $0.00
- Day range
- $52.98 – $53.01
- 52-week range
- $29.43 – $90.32
- 1-day performance
- 0.00%
- 1-year performance
- 80.12%
- Current drawdown (1Y)
- -41.31%
- CIK
- 0001484565
- CUSIP
- 834203309
- ISIN
- US8342033094
- Created
- 07/12/2025, 14:16:21
- Last update
- 23/09/2026, 17:40:26
Track Soleno Therapeutics, Inc. with an AI analyst
See which prediction-market events move SLNO, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens Berman
PRNewsWire • STOCK • 11/05/2026, 15:32:00
SOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO
Newsfile Corp • STOCK • 06/05/2026, 00:51:00
Soleno Therapeutics (NASDAQ: SLNO): Earnings, Legal Challenges, and Financial Health Insights
Market Data • Market Data • 05/05/2026, 22:00:25
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO
GlobeNewsWire • STOCK • 05/05/2026, 19:16:00
SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
PRNewsWire • STOCK • 05/05/2026, 14:34:00
SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO
Newsfile Corp • STOCK • 05/05/2026, 00:46:00
SOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff Deadline
GlobeNewsWire • STOCK • 04/05/2026, 19:47:00
SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO
GlobeNewsWire • STOCK • 04/05/2026, 14:21:00
SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
Newsfile Corp • STOCK • 04/05/2026, 14:20:00
SLNO SHAREHOLDER NOTICE: Hagens Berman Alerts Soleno (SLNO) Investors to Pending Securities Fraud Class Action and Upcoming May 5th Lead Plaintiff Deadline
GlobeNewsWire • STOCK • 04/05/2026, 10:45:00
Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO
PRNewsWire • STOCK • 04/05/2026, 06:03:00
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PRNewsWire • STOCK • 04/05/2026, 05:06:00